Nov. 14 at 6:47 PM
$CERO Excerpt from Maxim's Jason McCarthy review earlier this month:
"Hold recommendation. Our fundamentally positive view of CERo's CER-1236 CART program and opportunies in r/r AML remain unchanged. Our Hold rating is predicated on the 10/31 delisting of CERO shares from NASDAQ, the result of which
we believe triggered the conversion of existing convertible preferred stock. We view this as a positive that better positions the company to work its way back to NASDAQ.
Critical to this, in our view, is likely to be the initial response data for CER-1236 in r/r AML which could come in the next few months, possibly as early as the American Society for Hematology (ASH) meeting in December. The second cohort initiated today (11/5) with the first patient being dosed with a higher dose of cells as the dose escalation phase of the program continues."
